Literature DB >> 21166501

Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis.

Yan-Feng Zou1, Feng-Lai Yuan, Xiao-Liang Feng, Jin-Hui Tao, Ning Ding, Fa-Ming Pan, Fang Wang.   

Abstract

The aim of our meta-analysis was to assess the association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk. Eleven studies that included data from 2,743 cases and 2,195 controls were identified. When all groups were pooled, we did not detect the association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk. In the subgroup analysis, we detected the association of NFKB1 -94ins/delATTG promoter polymorphism with cancer in Caucasian population. The association also was found in Asian population. This meta-analysis demonstrates the association of NFKB1 -94ins/delATTG promoter polymorphism with cancer in Caucasian and Asian populations, and this association is ethno-specific.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21166501     DOI： 10.3109/07357907.2010.535054

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  12 in total

1.  Risk association between the NF-κB1 -94ins/delATTG promoter polymorphism and inflammatory bowel diseases: a meta-analysis.

Authors:  Meilan Liang; Xinyu Xu; Yaoyao Gong; Yurong Tang; Lin Lin
Journal:  Dig Dis Sci       Date:  2012-07-25       Impact factor: 3.199

2.  NFKB1 -94 insertion/deletion polymorphism and cancer risk: a meta-analysis.

Authors:  Linlin Xu; Shaoyi Huang; Wei Chen; Zhichun Song; Shu Cai
Journal:  Tumour Biol       Date:  2014-02-16

3.  The Establishment of the First Cancer Tissue Biobank at a Hispanic-Serving Institution: A National Cancer Institute-Funded Initiative between Moffitt Cancer Center in Florida and the Ponce School of Medicine and Health Sciences in Puerto Rico.

Authors:  Idhaliz Flores; Teresita Muñoz-Antonia; Jaime Matta; Miosotis García; David Fenstermacher; Sylvia Gutierrez; Edward Seijo; Jose' Torres-Ruiz; W Jack Pledger; Domenico Coppola
Journal:  Biopreserv Biobank       Date:  2011-11-10       Impact factor: 2.300

Review 4.  The diverse and complex roles of NF-κB subunits in cancer.

Authors:  Neil D Perkins
Journal:  Nat Rev Cancer       Date:  2012-01-19       Impact factor: 60.716

5.  Common Polymorphisms in the NFKBIA Gene and Cancer Susceptibility: A Meta-Analysis.

Authors:  Meng Zhang; Junjie Huang; Xiuxiu Tan; Jian Bai; Hao Wang; Yukun Ge; Hu Xiong; Jizhou Shi; Wei Lu; Zhaojie Lv; Chaozhao Liang
Journal:  Med Sci Monit       Date:  2015-10-21

Review 6.  An updated meta-analysis of 37 case-control studies on the association between NFKB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility.

Authors:  Yi-Qiao Luo; Duan Wang; Teng Gong; Jiang Zhu
Journal:  Oncotarget       Date:  2016-09-06

7.  Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features.

Authors:  Chao-Wen Cheng; Jen-Liang Su; Chiao-Wen Lin; Chun-Wen Su; Chun-Han Shih; Shun-Fa Yang; Ming-Hsien Chien
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

8.  Investigation of NF-κB1 and NF-κBIA gene polymorphism in non-small cell lung cancer.

Authors:  Y M Oltulu; E Coskunpinar; G Ozkan; E Aynaci; P Yildiz; T Isbir; I Yaylim
Journal:  Biomed Res Int       Date:  2014-02-23       Impact factor: 3.411

9.  Association of common polymorphisms in TNFA, NFkB1 and NFKBIA with risk and prognosis of esophageal squamous cell carcinoma.

Authors:  Meenakshi Umar; Rohit Upadhyay; Shaleen Kumar; Uday Chand Ghoshal; Balraj Mittal
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

Review 10.  Association between NFKB1 -94ins/del ATTG Promoter Polymorphism and Cancer Susceptibility: An Updated Meta-Analysis.

Authors:  Xiao Yang; Pengchao Li; Jun Tao; Chao Qin; Qiang Cao; Jinbao Gu; Xiaheng Deng; Jun Wang; Xuzhong Liu; Zijie Wang; Bian Wu; Min Gu; Qiang Lu; Changjun Yin
Journal:  Int J Genomics       Date:  2014-05-07       Impact factor: 2.326
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.